Get started
Author

Hugo Luzardo

Observed names: H. D. Luzardo, H. Luzardo, H.D. Luzardo, Hugo Daniel Luzardo Henriquez, Hugo Daniel Luzardo Henríquez, Hugo Luzardo Henriquez, Hugo Luzardo Henríquez, Hugo Luzardo-Henríquez
ORCID: 0000-0003-3327-1299
Observed ORCID: 0000-0003-3327-1299
OpenAlex ID: A5082339454
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
2022 · Mi Kwon, Gloria Iacoboni, et al. · Haematologica · 149
PDF
New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta‐2 microglobulin in patients with diffuse large B‐cell lymphoma treated with R‐CHOP: Spanish Lymphoma Group Experience (GELTAMO)
2019 · Leyre Bento, Antonio Díaz‐López, et al. · British Journal of Haematology · 67
PDF
Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy
2024 · Gloria Iacoboni, Josu Iraola‐Truchuelo, et al. · HemaSphere · 47
PDF
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
2022 · Mariana Bastos-Oreiro, Antonio Gutierrez, et al. · Frontiers in Immunology · 44
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group
2020 · Mariana Bastos-Oreiro, Ana Muntañola, et al. · Annals of Hematology · 38
Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy
2022 · Gloria Iacoboni, Josu Iraola-Truchuelo, et al. · Blood · 19
Relevance of renin expression by real-time PCR in acute myeloid leukemia
2006 · Silvia de la Iglesia Iñigo, María Teresa Gómez Casares, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 16
Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study
2023 · Mariana Bastos-Oreiro, Antonio Gutierrez, et al. · Transplantation and Cellular Therapy · 8
PDF
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial
2023 · Josep-Maria Ribera, Mireia Morgades, et al. · Haematologica · 7
PDF
Positive Impact of Eculizumab Therapy on Surgery for Budd- Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Longterm History of Thrombosis
2016 · Silvia De-la-Iglesia, Hugo Luzardo, et al. · Hematology Reports · 7
PDF
Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia
2012 · Maria Perera, Alexia Suarez, et al. · Annals of Hematology · 7
The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia
2024 · María Nieves Saez Perdomo, Ruth Stuckey, et al. · Hematology Reports · 6
PDF
Extranodal natural killer/T‐cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets
2023 · Eva Gonzalez Barca, Laura Tomás‐Roca, et al. · American Journal of Hematology · 6
Outcomes of Patients With Lymphoma and Covid‐19: an Observational Cohort Study From Geltamo Spanish Group
2021 · A. Martín García‐Sancho, M. Izuzquiza, et al. · Hematological Oncology · 4
PDF
New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group
2024 · Mariana Bastos‐Oreiro, Pau Abrisqueta, et al. · HemaSphere · 3
PDF
Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era
2019 · Antonio Gutierrez, Leyre Bento, et al. · European Journal Of Haematology · 3
Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages
2022 · Alexia Suárez-Cabrera, Dolly Viviana Fiallo-Suárez, et al. · Diagnostics · 2
PDF
Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI
2025 · F. Martin-Moro, L. Bento, et al. · ESMO Open · 1
PDF
619 | Impact of Asct Consolidation and Rituximab Maintenance on Survival in Real‐world Patients With Mantle Cell Lymphoma in Spain. the Geltamo‐mcl‐2022 Study
2025 · A. Marin‐Niebla, M. Bastos‐Oreiro, et al. · Hematological Oncology · 1
PDF
Acute neurologic deterioration in a patient with asymptomatic Charcot-Marie-Tooth disease following three doses of Brentuximab-Vedotin
2024 · Haridian de la Nuez Melián, Hugo Luzardo Henríquez, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1
Integration of molecular testing for the personalized management of patients with diffuse large B-cell lymphoma and follicular lymphoma
2023 · Ruth Stuckey, Hugo Luzardo Henríquez, et al. · World Journal of Clinical Oncology · 1
PDF
Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study
2021 · Mariana Bastos-Oreiro, Antonio Gutierrez, et al. · Blood · 1
Real‐world resource utilization, toxicity management, and efficacy outcomes of CD20 × CD3 bispecific antibodies in B‐cell lymphoma: A study from the GELTAMO network
2026 · Mariana Bastos‐Oreiro, Gloria Iacoboni, et al. · HemaSphere
668 | Real‐world Evidence of Second‐line Therapy in Relapsed/refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study
2025 · L. Bento, M. Bastos‐Oreiro, et al. · Hematological Oncology
PDF
574 | Real‐world Outcomes and Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients With B‐cell Lymphoma—the Geltamo Experience
2025 · M. Bastos‐Oreiro, G. Iacoboni, et al. · Hematological Oncology
PDF
Works count: 41
Citation count: 438
H-index: 8
I10-index: 7
Year
Topic
Type